Literature DB >> 21054463

ABCG2 polymorphisms, 34G>A and 421C>A in a Korean population: analysis and a comprehensive comparison with other populations.

K-A Kim1, H-J Joo, J-Y Park.   

Abstract

BACKGROUND AND
OBJECTIVE: ABCG2, also known as Breast Cancer Resistance Peptide (BCRP) or mitoxantrone-resistant protein, is the second member of the G-family of ABC transporters. The frequencies of ABCG2 34G>A and 421C>A polymorphisms in a Korean population were assessed using a newly developed multiplex pyrosequencing method, and compared with the corresponding frequencies seen in other ethnic groups.
METHOD: We designed a multiplex pyrosequencing method to simultaneously detect ABCG2 421C>A and 34G>A polymorphisms and analysed the allele frequencies of these polymorphisms in 250 Korean subjects.
RESULTS: The results showed 100% concordance between single and multiplex pyrosequencing methods. We also validated the polymorphisms identified by pyrosequencing with a direct sequencing method using randomly selected samples. The allele frequencies of ABCG2 421C>A and 34G>A in the population tested were 0·298 and 0·190 respectively. The allele frequency of the 421C>A polymorphism is comparable to other Asian populations, including Japanese and Chinese. However, both frequencies are different from those of Caucasians and Africans.
CONCLUSIONS: The multiplex pyrosequencing method used to detect two ABCG2 polymorphisms concurrently is a rapid and reliable genotyping method for the detection of important ABCG2 genetic polymorphisms. The ABCG2 34G>A and 421C>A polymorphisms are frequently found in the Korean population. The frequencies are similar to those seen in other Asian populations including Japanese and Chinese, but very different to those of Caucasian and African-American populations.
© 2010 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21054463     DOI: 10.1111/j.1365-2710.2009.01127.x

Source DB:  PubMed          Journal:  J Clin Pharm Ther        ISSN: 0269-4727            Impact factor:   2.512


  14 in total

1.  Effect of ABCG2 genotypes on the pharmacokinetics of A771726, an active metabolite of prodrug leflunomide, and association of A771726 exposure with serum uric acid level.

Authors:  Kyoung-Ah Kim; Hyun-Jin Joo; Ji-Young Park
Journal:  Eur J Clin Pharmacol       Date:  2010-10-23       Impact factor: 2.953

2.  Pharmacokinetic drug interactions of the selective androgen receptor modulator GTx-024(Enobosarm) with itraconazole, rifampin, probenecid, celecoxib and rosuvastatin.

Authors:  Christopher C Coss; Amanda Jones; James T Dalton
Journal:  Invest New Drugs       Date:  2016-04-22       Impact factor: 3.850

3.  Q141K polymorphism of ABCG2 protein is associated with poor prognosis in adult acute myeloid leukemia treated with idarubicin-based chemotherapy.

Authors:  Mario Tiribelli; Dora Fabbro; Alessandra Franzoni; Renato Fanin; Giuseppe Damante; Daniela Damiani
Journal:  Haematologica       Date:  2012-10-12       Impact factor: 9.941

4.  Toxicity of weekly oral topotecan in relation to dosage for gynecologic malignancies: a phase I study.

Authors:  Vivian E von Gruenigen; Heidi E Frasure; Deborah A Smith; Nancy L Fusco; Susan M Eaton; Robert L DeBernardo; Anne M Heugel; Steven E Waggoner
Journal:  Anticancer Drugs       Date:  2012-08       Impact factor: 2.248

5.  Pharmacodynamics and pharmacokinetics of oral topotecan in patients with advanced solid tumours and impaired renal function.

Authors:  Lot A Devriese; Petronella Els O Witteveen; Marja Mergui-Roelvink; Deborah A Smith; Lionel D Lewis; David S Mendelson; Yung-Jue Bang; Hyun Choel Chung; Mohammed M Dar; Alwin D R Huitema; Jos H Beijnen; Emile E Voest; Jan H M Schellens
Journal:  Br J Clin Pharmacol       Date:  2015-05-20       Impact factor: 4.335

6.  Impact of ABCG2 polymorphisms on the clinical outcome of TKIs therapy in Chinese advanced non-small-cell lung cancer patients.

Authors:  Xueqin Chen; Dadong Chen; Shaoyu Yang; Ruobing Ma; Yuelong Pan; Xin Li; Shenglin Ma
Journal:  Cancer Cell Int       Date:  2015-04-19       Impact factor: 5.722

7.  Sunitinib-induced severe toxicities in a Japanese patient with the ABCG2 421 AA genotype.

Authors:  Yuji Miura; Chiyo K Imamura; Koya Fukunaga; Yoshihiko Katsuyama; Koichi Suyama; Toshikazu Okaneya; Taisei Mushiroda; Yuichi Ando; Toshimi Takano; Yusuke Tanigawara
Journal:  BMC Cancer       Date:  2014-12-16       Impact factor: 4.430

8.  SLCO2B1 genetic polymorphisms in a Korean population: pyrosequencing analyses and comprehensive comparison with other populations.

Authors:  Kyoung-Ah Kim; Hyun-Jin Joo; Hae-Mi Lee; Ji-Young Park
Journal:  Mol Biol Rep       Date:  2013-05-11       Impact factor: 2.316

9.  Genetic Variations in ABCG2 Gene Predict Breast Carcinoma Susceptibility and Clinical Outcomes after Treatment with Anthracycline-Based Chemotherapy.

Authors:  Huizhe Wu; Yong Liu; Hui Kang; Qinghuan Xiao; Weifan Yao; Haishan Zhao; Enhua Wang; Minjie Wei
Journal:  Biomed Res Int       Date:  2015-11-08       Impact factor: 3.411

10.  ABCG2 in peptic ulcer: gene expression and mutation analysis.

Authors:  Aleksandra Salagacka-Kubiak; Marta Żebrowska; Agnieszka Wosiak; Mariusz Balcerczak; Marek Mirowski; Ewa Balcerczak
Journal:  J Appl Genet       Date:  2015-11-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.